Transcenta Holding Limited-B (06628): The invention patent application for "Anti-CLDN18.2 Antibody and Its Diagnostic Use" has been granted an invention patent by the China National Intellectual Property Administration.

Zhito Finance APP news, Transcenta Holding Pharmaceuticals-B (06628) announced that the invention patent application titled "Anti-CLDN18.2 Antibody and Its Diagnostic Use" (Application No.: CN202180041601.5), submitted by Suzhou Transcenta Pharmaceutical Group Co., Ltd. (Suzhou Transcenta), a wholly-owned subsidiary of the Company, has been granted an invention patent by the China National Intellectual Property Administration (CNIPA), with the grant publication number CN115836090B and the grant publication date of September 25, 2026 (the Patent).